Clinical trials: Clinically Isolated Syndrome, CNS Demyelinating
Multiple Sclerosis, Clinically Isolated Syndrome
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
The study aims at identifying the type of B and CD4 T cell subsets with pathogenic properties in the different clinical forms of multiple sclerosis.
- Trial name
- T4MS (NCT04798651)
- Testing
- blood sample, cerebro-spinal fluid
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Bordeaux
Multiple Sclerosis
Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice
This was a retrospective cohort study using the electronic medical record (EMR) database from Cleveland Clinic. The data was analyzed at start of ofatumumab (OMB) therapy (baseline, defined as 6 months prior to OMB initiation)…
- Trial name
- NCT06737419
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better.
- Trial name
- NCT06220669
- Testing
- LY3541860
- Where
- 20 sites in United States, France and 5 more
- Volunteers
- 63 people
- Sponsor
- Eli Lilly and Company
Clinically Isolated Syndrome, Relapsing-Remitting Multiple Sclerosis
Mitochondrial Dysfunction and Disease Progression
While the last several years have seen great strides in the treatment of relapsing forms of MS, progressive MS, responsible for the majority of MS-related disability, lags far behind.
- Conditions
- Clinically Isolated Syndrome, Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- Trial name
- NCT02549703
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Multiple Sclerosis
EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis
The primary purpose is to determine the changes in gene expression induced by IFNb-1a (Rebif) and atorvastatin (Lipitor) combination therapy in patients with an isolated clinical syndrome suggestive of multiple sclerosis (MS), to…
- Trial name
- NCT00137176
- Testing
- Rebif
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Multiple Sclerosis (MS) is a chronic inflammatory \& degenerative disease of the central nervous system (CNS) Recent data from the MS Base registry demonstrated an average delay of 152 - 215 days between first presentation and…
- Trial name
- AttackMS (NCT05418010)
- Testing
- Tyruko Injectable Product
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Queen Mary University of London
Multiple Sclerosis
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
The planned study will be a prospective, non-interventional, observational cohort study using the structure of a registry. Medication usage behavior will be observed for 6 months, while documentation behavior on the wellness…
- Trial name
- PROmyBETAapp (NCT03134573)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046), Betaconnect auto-injector, myBETAapp
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Bayer
Clinically Isolated Syndrome, Multiple Sclerosis
Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome
The primary purpose of this study is to assess the immune response to vitamin D supplementation at two doses (5,000 IU and 10,000 IU daily) in both healthy controls and patients with clinically isolated syndrome compared to…
- Trial name
- CISAVID (NCT01728922)
- Testing
- 5000IU vitamin D, 10000IU vitamin D
- Where
- Ireland
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University College Dublin
Multiple Sclerosis, Clinically Isolated Syndrome
Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
PRISMA, is a pregnancy registry study, focused on comprehensively collecting information about pregnancy in women with chronic neurological conditions from across the United States and internationally.
- Conditions
- Multiple Sclerosis, Clinically Isolated Syndrome, NMOSD, Myasthenia Gravis
- Trial name
- NCT06940323
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Clinically Isolated Demyelinating Syndromes, Multiple Sclerosis
Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI
Clinically isolated demyelinating syndromes (CIS) can evolve into multiple sclerosis (MS). Cognitive deficiencies could occur at this early stage and concern mainly information processing speed (IPS) and their mechanisms are not…
- Conditions
- Clinically Isolated Demyelinating Syndromes, Multiple Sclerosis, Cognitive Deficiencies, Brain MRI
- Trial name
- SCI-COG (NCT01865357)
- Testing
- Brain MRI - Clinical and cognitive evaluation, Eye movement
- Where
- France
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
MS-ResearchBiomarkerS
This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- MS-ReBS (NCT05204459)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Multiple Sclerosis
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
The primary objective was to demonstrate the effect of teriflunomide (HMR1726) (14 milligram per day [mg/day] and 7 mg/day), in comparison to placebo, for reducing conversion of participants presenting with their first clinical…
- Trial name
- TOPIC (NCT00622700)
- Testing
- Teriflunomide
- Where
- 131 sites in United States, Australia and 19 more
- Volunteers
- 618 people
- Sponsor
- Sanofi
Pediatric Multiple Sclerosis
Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis
The purpose of this study is to better understand multiple sclerosis (MS) in children and adolescents, to learn if it differs from adult MS and to investigate if genes or environmental exposures or a combination of both put…
- Trial name
- NCT01396343
- Where
- 17 sites in United States
- Volunteers
- 1,276 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Multiple Sclerosis
Evaluation of Brain Atrophy in CIS Patients on Avonex
The purpose of this study is To examine if Avaonex can delay the development of clinically definite multiple sclerosis. To investigate if Avonex can delay disability progression by slowing brain atrophy.
- Trial name
- NCT01592474
- Volunteers
- 180 people
- Sponsor
- University at Buffalo
Multiple Sclerosis, Radiologically Isolated Syndrome
Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study
The goal of the PROCLAIM study is to assess the effectiveness of quantitative brain MRI, as measured by icobrain mr, on the detection of disease activity in multiple sclerosis, including the identification of smouldering disease…
- Conditions
- Multiple Sclerosis, Radiologically Isolated Syndrome, Clinically Isolated Syndrome
- Trial name
- PROCLAIM (NCT07032246)
- Testing
- quantitative brain MRI (icobrain mr), Standard of Care (SOC)
- Where
- 6 sites in Czechia, Germany and 1 more
- Volunteers
- 750 people
- Sponsor
- icometrix
Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
The purpose of this study is to further evaluate the safety and efficacy of Tovaxin in the treatment of relapsing forms of multiple sclerosis.
- Trial name
- OLTERMS (NCT00595920)
- Testing
- Tovaxin
- Where
- 27 sites in United States
- Volunteers
- 116 people
- Sponsor
- Opexa Therapeutics, Inc.
Multiple Sclerosis, Magnetic Resonance Imaging
Risk Factors in Early Multiple Sclerosis
The central hypothesis of this protocol is that it is possible, using First Degree Relatives (FDRs) of patients with Multiple Sclerosis (MS) and assessing a variety of both known and unknown risk factors for MS, to define a risk…
- Conditions
- Multiple Sclerosis, Magnetic Resonance Imaging, Biomarkers, Clinically Isolated Syndrome
- Trial name
- RISEMS (NCT03586986)
- Testing
- Brain MRI
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis (MS), Clinically Isolated Syndrome (CIS)
Pregnancy Cohort in Multiple Sclerosis (MS)
Multiple sclerosis (MS) is a common inflammatory demyelinating disorder of the central nervous system frequently affecting females in their reproductive phase of life.
- Trial name
- NCT05010902
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Multiple Sclerosis, Clinically Isolated Syndrome (CIS)
Prebiotic vs Probiotic in Multiple Sclerosis
This is a randomized crossover-designed study to explore the immunologic effects of Prebiotics, as opposed to direct supplementation with beneficial bacteria (Probiotics) in the immune system of patients with MS and Clinically…
- Trial name
- MS (NCT04038541)
- Testing
- Prebiotics (Prebiotin Prebiotic Fiber Stick Pac), Probiotics (Visbiome®)
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Columbia University
Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis
Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis
This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be…
- Trial name
- NCT05277740
- Testing
- Eye-tracking
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- McGill University